BIOLASE Stock Price, News & Analysis

BIOLASE, Inc. (BIOL) is a medical device company focused on the development, manufacturing, marketing, and sale of laser systems used in dentistry and medicine. The company’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Its products are described as advancing the practice of dentistry and medicine for patients and healthcare professionals by aiming to provide biologically and clinically superior performance with less pain and faster recovery times.

According to company disclosures, BIOLASE’s proprietary laser products incorporate a large portfolio of patented and patent-pending technologies. As of December 31, 2023, the company reported approximately 241 active patents and 21 patent-pending technologies embedded in its laser platforms. From 1998 through December 31, 2023, BIOLASE stated that it had sold over 47,700 laser systems in more than 80 countries, reflecting broad geographic adoption of its dental laser technology.

Core business and product focus

BIOLASE develops and manufactures laser systems that are used in dental practices and other medical settings. The company describes its principal products as dental laser systems designed to support a wide range of procedures, including cosmetic treatments and complex surgical applications. These systems are positioned to help dentists and other clinicians perform procedures with reduced pain and faster recovery for patients compared with traditional methods, based on the company’s characterization of its technology.

In addition to laser systems, BIOLASE reports revenue from consumable products, such as disposable tips used with its installed base of lasers, as well as other related revenue categories. The company has highlighted recurring revenue subscriptions related to consumables as an element of its business, and has noted strong consumable sales performance in recent financial updates. BIOLASE also indicates that it continues to develop laser products that address its core dental market and adjacent medical and consumer applications.

Dental laser technology and applications

BIOLASE describes itself as a global or globally recognized leader in dental laser technology and as a global leader in dental lasers. Its systems are used for all-tissue and soft-tissue applications in dentistry. The company’s communications reference all-tissue dental lasers under the Waterlase brand and soft-tissue diode laser offerings under the Epic brand. BIOLASE has emphasized that its dental laser systems can be used across disciplines such as restorative dentistry, periodontics, endodontics, pediatric dentistry, and dental hygiene, based on topics covered in its educational programs.

The company has also highlighted Er,Cr:YSGG laser technology in connection with periodontal and implant procedures, noting clinical advantages in periodontal and implant health and describing this technology as supporting more predictable, comfortable, and minimally invasive treatment pathways. BIOLASE has referenced all-tissue laser technology and YSGG lasers in the context of periodontal and implant care and practice growth.

Installed base, education, and clinical adoption

With tens of thousands of laser systems sold over multiple decades, BIOLASE points to an installed base that generates ongoing demand for consumables and educational support. The company has reported record consumable sales and the introduction of recurring revenue subscriptions, as well as increased utilization of its installed base, as indicators of adoption. It has also cited increased adoption of its laser systems and higher sales conversion rates in connection with its Waterlase Trial Program.

BIOLASE supports education and training through initiatives such as the Waterlase Academy and Epic Diode Academy and through its online education portal. The company offers on-demand webinars, classroom and virtual course offerings, clinical animation videos, and case videos. Its “Let’s Talk Dental” webinar series covers topics including restorative dentistry, periodontics, endodontics, pediatric dentistry, and dental hygiene, and features clinicians and consultants discussing clinical applications, billing, coding, and revenue topics related to modern dental practices and laser use.

Product development and technology features

BIOLASE continues to introduce new laser systems and enhancements. The company launched the Waterlase iPlus Premier Edition, described as a state-of-the-art all-tissue laser system and an update to the Waterlase iPlus platform. Reported features of the Waterlase iPlus Premier Edition include a modular software design that allows clinicians to select procedure packages and add capabilities as their practices evolve, a larger touchscreen display, an improved graphical user interface, on-board technique animations and protocol guides, startup and shutdown wizards, and Wi‑Fi connectivity for remote diagnostics and support. These features are presented by the company as improving user experience, streamlining upkeep, and supporting continuous practice operation.

BIOLASE has also highlighted YSGG laser solutions for periodontal and implant care, including Er,Cr:YSGG technology, and has showcased these systems at major dental meetings. The company notes that its laser technology is intended to enhance clinical outcomes, improve patient comfort, and support efficiency and practice expansion.

Market presence and trading status

BIOLASE has described itself as the globally recognized or global leader in dental laser technology and as the world’s leading innovator in dental laser technology in certain communications. Its lasers are reported to be in use in over 80 countries, and the company has participated in major industry events such as the Greater New York Dental Meeting and the Chicago Midwinter Meeting to demonstrate its products and engage with clinicians.

Historically, BIOLASE’s common stock traded on The Nasdaq Stock Market under the symbol BIOL. On June 18, 2024, the company announced that Nasdaq had determined to delist BIOLASE’s common stock due to failure to satisfy the minimum bid price requirement and minimum stockholders’ equity requirement for continued listing. Suspension of trading on Nasdaq was scheduled to be effective at the open of trading on June 20, 2024. BIOLASE stated that it expected its common stock to commence trading on the OTC Markets Group platform on June 20, 2024, under the symbol BIOL and that it had applied to trade on the OTCQB Market.

Bankruptcy proceedings and sale process

On October 1, 2024, BIOLASE announced that it and its direct domestic subsidiaries had voluntarily initiated Chapter 11 proceedings in the United States Bankruptcy Court for the District of Delaware. The company stated that it would seek court approval to continue operating during the proceedings and that it remained focused on providing customers with its dental lasers and customer service. BIOLASE also reported that it was pursuing a sale process under Section 363 of the Bankruptcy Code and that it had entered into an asset purchase agreement with Sonendo Inc., under which Sonendo would acquire substantially all of the assets of BIOLASE through a court-supervised auction process, subject to court approval and other conditions. BIOLASE indicated that this bid would serve as a starting point for the sale process and that it could not be certain that securityholders would receive any payment or distribution on account of their shares following such sales.

The company further disclosed that it had received a commitment for debtor-in-possession financing intended to support operations during the Chapter 11 process, including payment of employee wages and benefits and continued servicing of customer orders and shipments. BIOLASE engaged advisors to evaluate strategic options, including a potential sale of all or some of its assets in connection with the bankruptcy petitions.

Financial reporting and performance context

BIOLASE regularly reports financial results, including net revenue, gross margin, operating expenses, and operating loss. The company has discussed revenue contributions from U.S. and international laser sales, consumables and other revenue, and the impact of cost reduction efforts on gross margin and operating expenses. It has also provided guidance on expected full-year revenue and Adjusted EBITDA and has used non‑GAAP measures such as Adjusted EBITDA to describe its view of core operating performance. BIOLASE has highlighted trends such as increased consumable revenue, recurring subscriptions, and cost savings from in-house manufacturing of certain components.

Educational and clinical engagement

Beyond product development and sales, BIOLASE emphasizes clinician education and clinical engagement. Its webinar series and educational portal are intended to help dental clinicians learn about laser-assisted procedures across multiple specialties. The company’s communications reference lectures and webinars led by periodontists, prosthodontists, pediatric dentists, dental hygienists, and dental consultants, covering clinical techniques, myofunctional therapy topics, and practice management subjects such as billing and coding for modern dental practices using laser technology.

Summary

In summary, BIOLASE, Inc. is a medical device manufacturer in the dental equipment and supplies manufacturing space, with a primary focus on dental laser systems used in dentistry and medicine. The company reports a long history of laser system sales worldwide, a substantial patent portfolio, and an emphasis on minimally invasive, laser-based dental procedures. At the same time, BIOLASE has faced financial and listing challenges, including delisting from Nasdaq in 2024 and voluntary Chapter 11 proceedings accompanied by a planned sale of substantially all of its assets, as disclosed in its public announcements.